SE544131C2 - Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof - Google Patents

Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof

Info

Publication number
SE544131C2
SE544131C2 SE2050286A SE2050286A SE544131C2 SE 544131 C2 SE544131 C2 SE 544131C2 SE 2050286 A SE2050286 A SE 2050286A SE 2050286 A SE2050286 A SE 2050286A SE 544131 C2 SE544131 C2 SE 544131C2
Authority
SE
Sweden
Prior art keywords
ssao
free
heteroatom
substance
organic group
Prior art date
Application number
SE2050286A
Other versions
SE2050286A1 (en
Inventor
Thomas Engstrand
Bowden Tim Melander
Original Assignee
Pvac Medical Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pvac Medical Tech Ltd filed Critical Pvac Medical Tech Ltd
Priority to SE2050286A priority Critical patent/SE544131C2/en
Priority to PCT/EP2021/056698 priority patent/WO2021185844A1/en
Priority to PCT/EP2021/056694 priority patent/WO2021185842A1/en
Publication of SE2050286A1 publication Critical patent/SE2050286A1/en
Publication of SE544131C2 publication Critical patent/SE544131C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

A substance comprising a carrier exhibiting at least one scavenger structure,said scavenger structure comprising a nucleophilic centre complying with the formulawhereina) X1 is a single-bonded heteroatom selected amongst N, O and S and exhibits a free electron pair,b) m is 0 or 1 and n is 1 or 2 with the sum of m plus n being 2 for X1 = N and 1 for X1 = S and O,c) -R”- is a bivalent organic group providing attachment to the carrier via one of its free valences and direct attachment to the heteroatom X1 at the other one of its free valences, andd) R’- is a monovalent organic group directly attached to the heteroatom X1 via its free valencefor use as a medicament for blocking or inhibiting semicarbazide sensitive amine oxidase (SSAO), preferably blocking or inhibiting SSAO expressed and produced by vascular smooth muscle cells and/or endothelial cells and/or soluble SSAO.
SE2050286A 2020-03-16 2020-03-16 Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof SE544131C2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE2050286A SE544131C2 (en) 2020-03-16 2020-03-16 Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
PCT/EP2021/056698 WO2021185844A1 (en) 2020-03-16 2021-03-16 Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
PCT/EP2021/056694 WO2021185842A1 (en) 2020-03-16 2021-03-16 Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE2050286A SE544131C2 (en) 2020-03-16 2020-03-16 Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof

Publications (2)

Publication Number Publication Date
SE2050286A1 SE2050286A1 (en) 2021-09-17
SE544131C2 true SE544131C2 (en) 2022-01-04

Family

ID=75111578

Family Applications (1)

Application Number Title Priority Date Filing Date
SE2050286A SE544131C2 (en) 2020-03-16 2020-03-16 Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof

Country Status (2)

Country Link
SE (1) SE544131C2 (en)
WO (1) WO2021185842A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022191759A1 (en) * 2021-03-09 2022-09-15 Cremed AB (publ) A polymer-based carbonyl scavenger for detection and treatment of ischemic injuries

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311182A1 (en) * 2004-03-31 2009-12-17 Dong Wang Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
US20120189627A1 (en) * 2007-11-02 2012-07-26 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
EP2670439A1 (en) * 2011-01-31 2013-12-11 Bowden, Tim Active principle for mitigating undesired medical conditions
EP2886534A1 (en) * 2008-05-30 2015-06-24 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
TWI437986B (en) * 2008-01-31 2014-05-21 R Tech Ueno Ltd Thiazole derivative and use thereof as vap-1 inhibitor
EP2254944B1 (en) 2008-02-29 2018-12-19 PVAC Medical Technologies Ltd. Composition for the formation of gels
WO2018172422A1 (en) * 2017-03-21 2018-09-27 Pvac Medical Technologies Ltd Method of preserving erythrocytes using pvac
WO2019016189A1 (en) * 2017-07-18 2019-01-24 Pvac Medical Technologies Ltd Anti-bacterial substance and composition thereof, medical and non-medical uses using the same, and products comprising said substance and compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311182A1 (en) * 2004-03-31 2009-12-17 Dong Wang Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
US20120189627A1 (en) * 2007-11-02 2012-07-26 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
EP2886534A1 (en) * 2008-05-30 2015-06-24 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
EP2670439A1 (en) * 2011-01-31 2013-12-11 Bowden, Tim Active principle for mitigating undesired medical conditions

Also Published As

Publication number Publication date
WO2021185842A1 (en) 2021-09-23
SE2050286A1 (en) 2021-09-17

Similar Documents

Publication Publication Date Title
CL2021002965A1 (en) Antiviral compounds containing nitrile.
RU2011137204A (en) ANTISEPTIC COMPOSITIONS AND THEIR APPLICATIONS
CN107412847A (en) A kind of Wound dressing of liquid form and preparation method thereof
Chen et al. Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine
RAO BANDARU et al. A Prospective Study of Postoperative Wound Infections in a Teaching Hospital of Rural Setup.
SE544131C2 (en) Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2020076760A3 (en) Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection
Traore et al. Impact of hydroxychloroquine-loaded polyurethane intravaginal rings on lactobacilli
US9248159B2 (en) MRSA bactericidal topical gel
He et al. An evaluation of norspermidine on anti-fungal effect on mature Candida albicans biofilms and angiogenesis potential of dental pulp stem cells
Febriyenti et al. Honey gel and film for burn wound
Fraire Aeromonas hydrophila infection
Lawrence et al. Toxicity of ethylene chlorohydrin I: Acute toxicity studies
MX9304197A (en) NEW USE OF LYSOZINE DIMER AND COMPOSITIONS CONTAINING IT.
CN110198731B (en) Antimicrobial composition comprising sodium dimercaptopropane sulfonate and dimethyl sulfoxide, use of the composition, and wound treatment methods using the same
FR2358893A1 (en) ANTIMICROBIAL COMPOSITION CONTAINING 1-IMIDAZOLYL-BUTANE-2-ONES OR -BUTANE-2-OLS HALOGENES
Sarakbi et al. Viability of microorganisms in novel chemical and biopharmaceutical anticancer drug solutions.
Stevens Surgical nutrition: the fourth coming
Hooker et al. Absorption of sulfanilamide from burned surfaces
JP6690816B2 (en) Disinfecting composition containing polyvinylpyrrolidone and unithiol and use of the composition
Simon et al. Crossing the Gulf of Aden: Cutaneous infections in African migrant shipwreck survivors
JPS63503540A (en) Anti-tumor film made of biodegradable polymer
RU2009140097A (en) APPLICATION OF A TETRANITROSIL IRON COMPLEX WITH THIOPHENOL AS AN ANTUMOR MEDICINE
McGregor et al. Diethylcarbamazine control of bancroftian filariasis
Thomas et al. Improvements in medicated tulle dressings

Legal Events

Date Code Title Description
NUG Patent has lapsed